Immunology Service, Maimonides Institute for Biomedical Research of Córdoba, University of Córdoba, Córdoba, Spain.
Viral Immunol. 2012 Feb;25(1):37-44. doi: 10.1089/vim.2011.0044. Epub 2012 Jan 10.
Changes in natural killer (NK) cells according to their phenotype and expression of certain regulatory receptors were analyzed in a double-blind, controlled study of antiretroviral therapy (ART)-untreated HIV-seropositive patients, who had been vaccinated with monocyte-derived dendritic cells pulsed with inactivated HIV-1 autologous virus. This work extends other recently published studies of the same group of HIV-1(+) vaccinated patients, which demonstrated that the viral load significantly decreases and correlates inversely with an increase in HIV-specific T-cell responses in vaccinated patients, but not in controls who received placebo. Our results indicate that this vaccine raises the level of the NK CD56(neg) cell subpopulation, while levels of the NK CD56(dim) and NK CD56(bright) cells expressing the inhibitory receptor CD85j/ILT-2 fell in vaccinated patients. Taken together, these results suggest that this vaccine might enhance innate immunity by amplifying the inflammatory and cytolytic capacity.
在一项双盲、对照研究中，分析了未经抗逆转录病毒治疗 (ART) 的 HIV 血清阳性患者的自然杀伤 (NK) 细胞根据其表型和某些调节性受体的表达的变化，这些患者接受了用灭活的 HIV-1 自体病毒冲击的单核细胞衍生树突状细胞进行了疫苗接种。这项工作扩展了同一组 HIV-1(+) 接种患者的其他最近发表的研究，这些研究表明，接种患者的病毒载量显著降低，并与 HIV 特异性 T 细胞反应的增加呈负相关，但在接受安慰剂的对照组中则没有。我们的结果表明，这种疫苗提高了 NK CD56(neg)细胞亚群的水平，而表达抑制性受体 CD85j/ILT-2 的 NK CD56(dim)和 NK CD56(bright)细胞的水平在接种患者中下降。总的来说，这些结果表明，这种疫苗可能通过增强炎症和细胞溶解能力来增强先天免疫。
